DSIP: the deep-sleep signal your body already makes

Your body makes a molecule that turns up in your blood right as you drop into your deepest sleep. Scientists first pulled it out of the brains of sleeping rabbits in the 1970s, and the name stuck: delta sleep-inducing peptide. DSIP. On the FDA’s paperwork it wears a second name — Emideltide — but it’s the same nine-amino-acid molecule. Which name you’ve run into depends on whether you were reading a sleep study or a Federal Register notice.

Here’s the idea that kept scientists interested for fifty years. A signal your own body already uses to reach deep sleep, handed back to you. If that worked the way the early animal work hinted, it would matter.

That if is the whole story. So let’s be straight about both halves of it.

What it could actually do for you

Two things, if the early signal holds.

The first is deep sleep — the real kind. Not just more hours, but more of the slow-wave stage: the part of the night where your body does its heavy repair and your brain clears itself out. That’s the stage DSIP is named for. In animals, giving it reliably pushed sleep toward exactly that stage. For anyone who logs eight hours and still wakes up flat, that’s the part worth wanting.

The second is a steadier stress system. DSIP has been studied for nudging the hormones your body runs on under pressure — cortisol and the signals sitting above it — toward a calmer setting. Plainly: taking some of the edge off the stress response. The two effects might even be one effect. Deep sleep and a calm stress axis are wired together, and a molecule that touches one tends to touch the other.

If both of those turned out real in humans, you’d have something close to a recovery switch. That’s the upside, and it’s a genuine one. Now the part that keeps it honest.

Why the biology is genuinely interesting

DSIP isn’t a lab invention. Your body already makes it, carries it through the brain and the bloodstream, and its levels rise and fall on a daily clock that peaks while you sleep. That last detail is what hooked the field. A molecule that shows up on schedule, right when you need deep sleep, looks an awful lot like part of the machinery that runs it.

The origin story is almost too clean. Take blood from a rabbit held in deep sleep, infuse it into an awake rabbit, and the awake one drifts into slow-wave sleep too. Something in that blood was carrying the sleep signal. That something was DSIP. Monnier and colleagues ran the original work in the 1970s, and it’s still the cleanest result in the whole file.

The trouble is what happened when the field tried to repeat it in people.

The honest boundary

Read this part twice, because it’s where DSIP earns its caveats.

The animal data was tidy. The human data never was. When researchers ran the most careful human sleep trial of the lot — Bes and colleagues, 1992, a double-blind study in sixteen chronic insomnia patients, measured with proper overnight sleep recordings — the primary result came back null. A few numbers drifted DSIP’s way, but the authors judged the effect weak, possibly a fluke in the placebo group, and put it bluntly: short-term DSIP is not likely to be of major therapeutic benefit for chronic insomnia. That’s the best-controlled human sleep trial there is, and it came back cold.

The stress-and-recovery findings sit on the same thin ground: small studies, decades old, using methods that wouldn’t clear a modern trial. Nobody has run the rigorous replication. And the mechanism — how DSIP actually does anything — was never pinned down. Fifty years in, no receptor for it has been definitively found. That’s a strange thing to still be missing on a molecule this old.

So here’s the calibration. The idea is genuinely interesting. The animal signal is real. But the one time it faced a proper human sleep trial, it didn’t deliver, and the biology underneath it is still half-dark. This is early-stage in the truest sense — earlier than the fifty-year paper trail makes it look. Hope with your eyes fully open.

Where the regulators sit

DSIP — under the name Emideltide — is on the FDA Pharmacy Compounding Advisory Committee’s July 24, 2026 docket, per Federal Register notice 2026-07361, with the reviewed uses listed as opioid withdrawal, chronic insomnia, and narcolepsy. It shares that day with Semax and Epitalon.

Worth clocking the gap there. The supplement market sells DSIP as a sleep-and-recovery peptide. What the FDA is actually weighing are three specific clinical conditions — and the opioid-withdrawal one rests on uncontrolled reports from the 1990s, with no controlled trial behind it. A PCAC review isn’t a drug approval either; it’s the narrower question of whether a compounding pharmacy can prepare the substance under set rules. What that review actually decides is its own story, told in what a PCAC review actually is.

On anti-doping: because DSIP is a peptide your body already makes, its status on the WADA list isn’t clear-cut, and we’re not going to pretend it is. If you’re tested, that’s a question for someone with sport-specific legal footing. Endogenous origin is not a clearance.

What happens next

The honest position on DSIP is the one the evidence supports: an interesting idea, a clean animal result, a null human trial, and a mechanism still in the dark. Not nothing. Not proven. Somewhere earlier than the hype wants it to be.

If that ever changes — if a modern, properly controlled trial finally gives DSIP the test it never got — the version worth paying attention to won’t be a vial off a research-chemical site. It’ll be a physician writing against a real indication, a licensed US pharmacy compounding it, and an assay on every batch. Wolverine Health exists to be that legitimate version, the day the science and the rules line up to allow it. July 24, 2026 is the next real marker on the calendar. Leave your email and we’ll tell you what the committee decides.